Analysts expect Abcellera Biologics to report a Q2 2026 revenue of $7.85 million and a loss per share of $0.17, with the current stock price of $5.83 trading significantly below the average analyst price target of $10.50.
Investors are primarily focused on the clinical readout timeline for ABCL635, a lead internal candidate for menopausal vasomotor symptoms with Phase 2 efficacy data anticipated in the second half of 2026.
Recent momentum has been supported by a new $28 million upfront collaboration with Vertex Pharmaceuticals focused on multispecific T-cell engager discovery. Market watchers are also closely monitoring the company's $650 million cash runway as it aggressively transitions from a discovery service platform to an internal clinical-stage biotechnology pipeline.